Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide and a major contributor to cardiometabolic morbidity. Notably, cardiovascular disease, rather than liver-related complications, is the leading cause of mortality among individuals with MASLD, highlighting the importance of accurate cardiovascular risk stratification in this population.1,2 Obesity represents a core component of the MASLD diagnostic framework;1,3,4 however, its definition has recently undergone substantial revision.
Journal of Hepatology published a clinical update in Research Highlights on 30 Jan 2026.
The item focuses on Obesity definitions reshape cardiovascular risk within MASLD.
Review the original article for the full source wording and details.